Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Adaptive Biotechnologies Corporation stock | $33.64

Learn how to easily invest in Adaptive Biotechnologies Corporation stock.

Adaptive Biotechnologies Corporation is a biotechnology business based in the US. Adaptive Biotechnologies Corporation shares (ADPT) are listed on the NASDAQ and all prices are listed in US Dollars. Adaptive Biotechnologies Corporation employs 622 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Adaptive Biotechnologies Corporation

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ADPT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Adaptive Biotechnologies Corporation stock price (NASDAQ: ADPT)

Use our graph to track the performance of ADPT stocks over time.

Adaptive Biotechnologies Corporation shares at a glance

Information last updated 2021-10-23.
Latest market close$33.64
52-week range$29.74 - $71.25
50-day moving average $35.39
200-day moving average $36.98
Wall St. target price$56.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.24

Buy Adaptive Biotechnologies Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Adaptive Biotechnologies Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Adaptive Biotechnologies Corporation price performance over time

Historical closes compared with the close of $33.64 from 2021-10-22

1 week (2021-10-13) 1.79%
1 month (2021-09-24) -7.81%
3 months (2021-07-23) -13.14%
6 months (2021-04-23) -21.89%
1 year (2020-10-23) -32.04%
2 years (2019-10-24) 29.38%
3 years (2018-10-20) N/A
5 years (2016-10-20) N/A

Adaptive Biotechnologies Corporation financials

Revenue TTM $133.4 million
Gross profit TTM $-40,220,000
Return on assets TTM -11.41%
Return on equity TTM -28%
Profit margin -128.33%
Book value $4.93
Market capitalisation $4.7 billion

TTM: trailing 12 months

Shorting Adaptive Biotechnologies Corporation shares

There are currently 4.4 million Adaptive Biotechnologies Corporation shares held short by investors – that's known as Adaptive Biotechnologies Corporation's "short interest". This figure is 4.7% up from 4.2 million last month.

There are a few different ways that this level of interest in shorting Adaptive Biotechnologies Corporation shares can be evaluated.

Adaptive Biotechnologies Corporation's "short interest ratio" (SIR)

Adaptive Biotechnologies Corporation's "short interest ratio" (SIR) is the quantity of Adaptive Biotechnologies Corporation shares currently shorted divided by the average quantity of Adaptive Biotechnologies Corporation shares traded daily (recently around 588421.7623498). Adaptive Biotechnologies Corporation's SIR currently stands at 7.49. In other words for every 100,000 Adaptive Biotechnologies Corporation shares traded daily on the market, roughly 7490 shares are currently held short.

However Adaptive Biotechnologies Corporation's short interest can also be evaluated against the total number of Adaptive Biotechnologies Corporation shares, or, against the total number of tradable Adaptive Biotechnologies Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Adaptive Biotechnologies Corporation's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Adaptive Biotechnologies Corporation shares in existence, roughly 30 shares are currently held short) or 0.0404% of the tradable shares (for every 100,000 tradable Adaptive Biotechnologies Corporation shares, roughly 40 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Adaptive Biotechnologies Corporation.

Find out more about how you can short Adaptive Biotechnologies Corporation stock.

Adaptive Biotechnologies Corporation share dividends

We're not expecting Adaptive Biotechnologies Corporation to pay a dividend over the next 12 months.

Adaptive Biotechnologies Corporation share price volatility

Over the last 12 months, Adaptive Biotechnologies Corporation's shares have ranged in value from as little as $29.735 up to $71.25. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Adaptive Biotechnologies Corporation's is 0.3018. This would suggest that Adaptive Biotechnologies Corporation's shares are less volatile than average (for this exchange).

Adaptive Biotechnologies Corporation overview

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test.

Frequently asked questions

What percentage of Adaptive Biotechnologies Corporation is owned by insiders or institutions?
Currently 1.332% of Adaptive Biotechnologies Corporation shares are held by insiders and 83.474% by institutions.
How many people work for Adaptive Biotechnologies Corporation?
Latest data suggests 622 work at Adaptive Biotechnologies Corporation.
When does the fiscal year end for Adaptive Biotechnologies Corporation?
Adaptive Biotechnologies Corporation's fiscal year ends in December.
Where is Adaptive Biotechnologies Corporation based?
Adaptive Biotechnologies Corporation's address is: 1165 Eastlake Avenue East, Seattle, WA, United States, 98102
What is Adaptive Biotechnologies Corporation's ISIN number?
Adaptive Biotechnologies Corporation's international securities identification number is: US00650F1093
What is Adaptive Biotechnologies Corporation's CUSIP number?
Adaptive Biotechnologies Corporation's Committee on Uniform Securities Identification Procedures number is: 00650F109

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site